Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medtronic at ESC: Encouraging Results From TAVR And Arrhythmia Genetics Studies, But Disappointment For HF Monitoring

This article was originally published in Clinica

Executive Summary

Results from three major trials sponsored by Medtronic made news at the 2015 ESC Congress in London, including more positive “real world” results with the CoreValve transcatheter aortic valve replacement system, evidence linking specific genes to abnormal heart rhythms, and disappointing results from a trial of heart failure management with Medtronic’s Optivol fluid status monitoring used in conjunction with Carelink remote cardiac rhythm management monitoring network.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel